NCT03809156View on ClinicalTrials.gov

Upfront Combination Pulmonary Arterial Hypertension Therapy

PHASE4UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 26, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

January 31, 2021

Conditions
Pulmonary Hypertension
Interventions
DRUG

Riociguat Oral Product

Dual therapy of Riociguat and Ambrisentan at initiation of treatment.

Trial Locations (2)

T1Y 6J4

RECRUITING

Peter Lougheed Center, Calgary

V5Z 1M9

RECRUITING

Vancouver General Hospital, The Lung Centre, Vancouver

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Calgary

OTHER